US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
US4215051A
(en)
|
1979-08-29 |
1980-07-29 |
Standard Oil Company (Indiana) |
Formation, purification and recovery of phthalic anhydride
|
US4456591A
(en)
|
1981-06-25 |
1984-06-26 |
Baxter Travenol Laboratories, Inc. |
Therapeutic method for activating factor VII
|
AU561343B2
(en)
|
1981-10-19 |
1987-05-07 |
Genentech Inc. |
Human immune interferon by recombinant dna
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
US4694778A
(en)
|
1984-05-04 |
1987-09-22 |
Anicon, Inc. |
Chemical vapor deposition wafer boat
|
US5189015A
(en)
|
1984-05-30 |
1993-02-23 |
Alfa-Laval Agri International Ab |
Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
|
US5077204A
(en)
|
1984-06-21 |
1991-12-31 |
Chiron Corporation |
Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
|
US4766073A
(en)
|
1985-02-25 |
1988-08-23 |
Zymogenetics Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
US4889919A
(en)
|
1986-08-13 |
1989-12-26 |
Zymogenetics, Inc. |
Biologically active PDGF derived A-chain homodimers
|
DK525384D0
(en)
|
1984-11-05 |
1984-11-05 |
Nordisk Insulinlab |
FACTOR PREPARATION VIII FOR THE TREATMENT OF HAEMOFILI A INHIBITOR PATIENTS AND PROCEDURE FOR THE PREPARATION OF SUCH A PREPARATION
|
US5157021A
(en)
|
1985-03-15 |
1992-10-20 |
Novo Nordisk A/S |
Insulin derivatives and pharmaceutical preparations containing these derivatives
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4868112A
(en)
|
1985-04-12 |
1989-09-19 |
Genetics Institute, Inc. |
Novel procoagulant proteins
|
GR860984B
(en)
|
1985-04-17 |
1986-08-18 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
US4745055A
(en)
|
1985-05-07 |
1988-05-17 |
California Biotechnology Inc. |
Fused protein for enzyme immunoassay system
|
KR910006424B1
(en)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
Method of manufacturing knitted briefs
|
US5180583A
(en)
|
1985-11-26 |
1993-01-19 |
Hedner Ulla K E |
Method for the treatment of bleeding disorders
|
WO1987004187A1
(en)
|
1986-01-03 |
1987-07-16 |
Genetics Institute, Inc. |
METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
|
US4786726A
(en)
|
1986-01-06 |
1988-11-22 |
Blood Systems, Inc. |
Factor IX therapeutic blood product, means and methods of preparing same
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
EP0832981A1
(en)
|
1987-02-17 |
1998-04-01 |
Pharming B.V. |
DNA sequences to target proteins to the mammary gland for efficient secretion
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
IE69026B1
(en)
|
1987-06-12 |
1996-08-07 |
Immuno Ag |
Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
US5892019A
(en)
|
1987-07-15 |
1999-04-06 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Production of a single-gene-encoded immunoglobulin
|
FR2619314B1
(en)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
|
US4994371A
(en)
|
1987-08-28 |
1991-02-19 |
Davie Earl W |
DNA preparation of Christmas factor and use of DNA sequences
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
JP2643968B2
(en)
|
1988-02-03 |
1997-08-25 |
サントリー株式会社 |
KEX2 endoprotease and method for producing the same
|
US5234830A
(en)
|
1988-02-03 |
1993-08-10 |
Suntory Limited |
DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990009800A1
(en)
|
1989-02-21 |
1990-09-07 |
Washington University |
Modified forms of reproductive hormones
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5766883A
(en)
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
SE8901687D0
(en)
|
1989-05-11 |
1989-05-11 |
Alfa Laval Agri Int |
FIBRONECTIN BINDING PROTEIN AS WELL AS IT'S PREPARATION
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
US5194596A
(en)
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
US5395760A
(en)
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
DK0417563T3
(en)
|
1989-09-12 |
2000-11-06 |
Hoffmann La Roche |
TNF-binding proteins
|
US5935815A
(en)
|
1989-10-25 |
1999-08-10 |
Katholieke Universiteit Leuven |
Process for micro biological production of proteins
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
SE465222C5
(en)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
A recombinant human factor VIII derivative and process for its preparation
|
US5648273A
(en)
|
1989-12-27 |
1997-07-15 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Hepatic growth factor receptor is the MET proto-oncogene
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
GB9009106D0
(en)
|
1990-04-23 |
1990-06-20 |
3I Res Expl Ltd |
Processes and intermediates for synthetic antibody derivatives
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5453491A
(en)
|
1990-09-11 |
1995-09-26 |
Kiyoshi Takatsu |
Murine interleukin-5 receptor
|
DK0574402T3
(en)
|
1990-11-26 |
1998-05-18 |
Chiron Corp |
Expression of PACE in Host Cells and Methods for Using Them
|
ATE164395T1
(en)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
|
ATE145428T1
(en)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
CHIMERIC CHAINS FOR TRANSDUCTION OF RECEPTOR-CONNECTED SIGNALING PATHWAYS
|
SG89295A1
(en)
|
1991-03-15 |
2002-06-18 |
Amgen Inc |
Pegylation of polypeptides
|
US5374617A
(en)
|
1992-05-13 |
1994-12-20 |
Oklahoma Medical Research Foundation |
Treatment of bleeding with modified tissue factor in combination with FVIIa
|
CA2102224A1
(en)
|
1991-04-19 |
1992-10-20 |
Toshio Kitamura |
Human interleukin-3-receptor component
|
WO1992021755A1
(en)
|
1991-05-31 |
1992-12-10 |
Genentech, Inc. |
Treatment of hiv-associated immune thrombocytopenic purpura
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US5227158A
(en)
|
1991-06-10 |
1993-07-13 |
Genentech, Inc. |
Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
|
US5346991A
(en)
|
1991-06-13 |
1994-09-13 |
Genentech, Inc. |
Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5116753A
(en)
|
1991-07-30 |
1992-05-26 |
The Salk Institute For Biological Studies |
Maintenance of pancreatic islets
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
AU676150B2
(en)
|
1992-01-23 |
1997-03-06 |
Merck Patent Gmbh |
Monomeric and dimeric antibody-fragment fusion proteins
|
FR2686899B1
(en)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
|
CA2128862C
(en)
|
1992-02-11 |
2008-05-20 |
Jonathan G. Seidman |
Homogenotization of gene-targeting events
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
WO1993024135A1
(en)
|
1992-05-26 |
1993-12-09 |
Immunex Corporation |
Novel cytokine that binds cd30
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
DK0627924T3
(en)
|
1992-10-02 |
2001-04-30 |
Genetics Inst |
Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
DE669986T1
(en)
|
1992-11-13 |
1996-10-10 |
Idec Pharma Corp |
COMPLETELY FUNCTIONAL CONSENSUS-KOZAK SEQUENCES FOR MAMMAL EXPRESSION.
|
US5726147A
(en)
|
1993-06-01 |
1998-03-10 |
The Scripps Research Institute |
Human mutant tissue factor compositions useful as tissue factor antagonists
|
US6518013B1
(en)
|
1993-06-07 |
2003-02-11 |
Trimeris, Inc. |
Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
|
US6479055B1
(en)
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
US5464933A
(en)
|
1993-06-07 |
1995-11-07 |
Duke University |
Synthetic peptide inhibitors of HIV transmission
|
US6017536A
(en)
|
1993-06-07 |
2000-01-25 |
Trimeris, Inc. |
Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
|
US5621039A
(en)
|
1993-06-08 |
1997-04-15 |
Hallahan; Terrence W. |
Factor IX- polymeric conjugates
|
US6310180B1
(en)
|
1993-06-21 |
2001-10-30 |
Vanderbilt University |
Method for synthesis of proteins
|
SE504074C2
(en)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Protein preparation for subcutaneous, intramuscular or intradermal administration
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US6740734B1
(en)
|
1994-01-14 |
2004-05-25 |
Biovitrum Ab |
Bacterial receptor structures
|
JPH09509054A
(en)
|
1994-02-01 |
1997-09-16 |
アメリカ合衆国 |
Fusion protein containing antibody portion and non-antibody portion
|
DE4405426A1
(en)
|
1994-02-21 |
1995-08-24 |
Boehringer Mannheim Gmbh |
Pharmaceutical preparation containing plasminogen activator (t-PA) or its derivatives
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
US5648240A
(en)
|
1994-05-24 |
1997-07-15 |
Texas A&M University |
MHC II analog from Staphylococcus aureus
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5596080A
(en)
|
1994-10-03 |
1997-01-21 |
E. I. Du Pont De Nemours And Company |
Crosslinking processes/agents for zein
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5591573A
(en)
|
1995-04-10 |
1997-01-07 |
Alpha Therapeutic Corporation |
Method and system for testing blood samples
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5579277A
(en)
|
1995-05-01 |
1996-11-26 |
Apple Computer, Inc. |
System and method for interleaving memory banks
|
US6184344B1
(en)
|
1995-05-04 |
2001-02-06 |
The Scripps Research Institute |
Synthesis of proteins by native chemical ligation
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US5811524A
(en)
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
BR9609152A
(en)
|
1995-06-07 |
1999-05-04 |
Trimeris Inc |
Process for treatment of HIV infection in an individual inhibition of HIV replication and acceptable pharmaceutical composition useful for the treatment of HIV infection
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US5840529A
(en)
|
1995-08-02 |
1998-11-24 |
Clinical Research Institute Of Montreal |
Mammalian pro-hormone convertase
|
EP1382679A3
(en)
|
1995-09-08 |
2004-11-10 |
Genentech, Inc. |
Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
|
SE9503380D0
(en)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
CA2198968C
(en)
|
1996-03-04 |
2010-02-09 |
Toyofumi Masuda |
Process for production of secretory kex2 derivatives
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
CA2258153C
(en)
|
1996-07-03 |
2004-08-17 |
Genentech, Inc. |
Hepatocyte growth factor receptor agonists and uses thereof
|
CA2203745A1
(en)
|
1996-07-26 |
1998-01-26 |
Robert Day |
Pro-protein converting enzyme
|
ES2300113T3
(en)
|
1996-08-02 |
2008-06-01 |
Bristol-Myers Squibb Company |
A PROCEDURE FOR INHIBITING TOXICITY INDUCED BY IMMUNOGLOBULINS RESULTING FROM THE USE OF IMMUNOGLOBULINS IN THERAPY AND IN VIVO DIAGNOSIS.
|
US6159462A
(en)
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
ZA977959B
(en)
*
|
1996-10-16 |
1998-03-23 |
Alza Corp |
Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.
|
IN184589B
(en)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6271349B1
(en)
|
1996-12-23 |
2001-08-07 |
Immunex Corporation |
Receptor activator of NF-κB
|
DE69738841D1
(en)
|
1996-12-23 |
2008-08-28 |
Immunex Corp |
LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
|
TW502011B
(en)
|
1997-02-05 |
2002-09-11 |
Ajinomoto Kk |
Process for producing n-long-chain acyl acidic amino acids or salts thereof
|
ATE455552T1
(en)
|
1997-02-14 |
2010-02-15 |
American Nat Red Cross |
EXPRESSION OF ACTIVE HUMAN FACTOR IX IN THE MAMMARY GLAND TISSUE OF TRANSGENIC ANIMALS
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
RO120148B1
(en)
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Vector system and method for integrating a dna fragment in the mammalian cells genome
|
ES2301198T3
(en)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
ARTIFICIAL POLYPEPTIDES OF ANTIBODIES.
|
DE69837170T2
(en)
|
1997-06-13 |
2007-11-22 |
Amylin Pharmaceuticals, Inc., San Diego |
Solid-phase native chemical ligation of unprotected or n-cysteine-protected peptides in aqueous solutions
|
US6310183B1
(en)
|
1997-09-10 |
2001-10-30 |
Novo Nordisk A/S |
Coagulation factor VIIa composition
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
US6008321A
(en)
|
1998-03-16 |
1999-12-28 |
Pharmacopeia, Inc. |
Universal linker for combinatorial synthesis
|
US6281331B1
(en)
|
1998-03-23 |
2001-08-28 |
Trimeris, Inc. |
Methods and compositions for peptide synthesis
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
EP1082137A4
(en)
|
1998-05-06 |
2004-05-19 |
Univ Temple |
REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE Fc$g(g)RI RECEPTOR
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6355782B1
(en)
|
1998-07-09 |
2002-03-12 |
Baylor College Of Medicine |
Hypohidrotic ectodermal dyplasia genes and proteins
|
JP2002520053A
(en)
|
1998-07-15 |
2002-07-09 |
ジェネンテック・インコーポレーテッド |
Tissue factor protein variants with improved affinity for coagulation factor FVII / FVIIA
|
CN1309770A
(en)
|
1998-07-31 |
2001-08-22 |
华莱士·E·卡罗尔 |
Method and apparatus for determining anticoagulant therapy factors
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU1262900A
(en)
|
1998-11-06 |
2000-05-29 |
Novo Nordisk A/S |
Method for the production of fvii
|
US6280994B1
(en)
|
1998-11-25 |
2001-08-28 |
Zymogenetics, Inc. |
Zace 1: a human metalloenzyme
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
DK1141014T3
(en)
|
1999-01-06 |
2005-04-11 |
Genentech Inc |
Insulin-like growth factor (IGF) in mutant variant
|
WO2000040612A1
(en)
|
1999-01-06 |
2000-07-13 |
Genentech, Inc. |
Insulin-like growth factor (igf) i mutant variants
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(en)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
|
US6602977B1
(en)
|
1999-04-19 |
2003-08-05 |
Biovitrum Ab |
Receptor structures
|
WO2001001749A2
(en)
|
1999-07-02 |
2001-01-11 |
Genentech, Inc. |
FVIIa ANTAGONISTS
|
US6469136B1
(en)
|
1999-07-07 |
2002-10-22 |
Trimeris, Inc. |
Methods and composition for peptide synthesis
|
JP2001151694A
(en)
|
1999-09-17 |
2001-06-05 |
Takeda Chem Ind Ltd |
Method for producing protein powder
|
DE19963859A1
(en)
|
1999-12-30 |
2001-07-12 |
Apotech Res & Dev Ltd |
Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins
|
JP5179689B2
(en)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Enhancing the half-life of antibody-based fusion proteins in the circulation
|
JP2003530838A
(en)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
Albumin fusion protein
|
DK1278763T3
(en)
|
2000-04-28 |
2007-06-11 |
Inflazyme Pharm Ltd |
3-Nitrogen-6,7-dioxygen steroids and related applications
|
AU2002218166A1
(en)
|
2000-09-08 |
2002-03-22 |
Universitat Zurich |
Collections of repeat proteins comprising repeat modules
|
US7138119B2
(en)
|
2000-09-15 |
2006-11-21 |
Progenics Pharmaceuticals, Inc. |
Compositions and methods for inhibition of HIV-1 infection
|
US7615537B2
(en)
|
2000-10-25 |
2009-11-10 |
Genzyme Corporation |
Methods for treating blood coagulation disorders
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US20030203845A1
(en)
|
2001-02-05 |
2003-10-30 |
Knudsen Jens Bjerre |
Combined use of factor VII polypeptides and factor IX polypeptides
|
US7419949B2
(en)
|
2001-07-16 |
2008-09-02 |
Novo Noridsk Healthcare A/G |
Single-dose administration of factor VIIa
|
BR0212035A
(en)
|
2001-09-04 |
2004-08-03 |
Merck Patent Gmbh |
Modified ix factor
|
ATE364632T1
(en)
|
2001-10-05 |
2007-07-15 |
Affimed Therapeutics Ag |
ANTIBODIES OF HUMAN ORIGIN FOR INHIBITING THROMBOCYTE AGGREGATION
|
FR2831170B1
(en)
|
2001-10-19 |
2004-03-19 |
Inst Nat Sante Rech Med |
MODIFIED PROTEINS C DIRECTLY ACTIVABLE WITH THROMBIN
|
US20030078180A1
(en)
|
2001-10-24 |
2003-04-24 |
Benchmark Research & Technology, Inc. |
Contaminant-tolerant foaming additive
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR101271635B1
(en)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Albumin fusion proteins
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
CN100343393C
(en)
|
2002-03-15 |
2007-10-17 |
布赖汉姆妇女医院 |
Central airway administration for systemic delivery of therapeutics
|
US7425619B2
(en)
|
2002-08-14 |
2008-09-16 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
EP1562972B1
(en)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
CN102139114A
(en)
|
2003-02-26 |
2011-08-03 |
尼克塔治疗公司 |
Polymer factor VIII moiety conjugates
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US20050281829A1
(en)
|
2003-05-06 |
2005-12-22 |
Hehir Cristina A T |
Fc chimeric proteins with anti-HIV drugs
|
AU2004238263A1
(en)
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP3552627A1
(en)
|
2003-05-06 |
2019-10-16 |
Bioverativ Therapeutics Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
US7212798B1
(en)
|
2003-07-17 |
2007-05-01 |
Cisco Technology, Inc. |
Adaptive AGC in a wireless network receiver
|
JP2005060378A
(en)
|
2003-07-28 |
2005-03-10 |
Yamanouchi Pharmaceut Co Ltd |
Freeze-dried preparation containing physiologically active protein
|
US20050152979A1
(en)
|
2003-09-05 |
2005-07-14 |
Cell Therapeutics, Inc. |
Hydrophobic drug compositions containing reconstitution enhancer
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
AU2004282984B2
(en)
|
2003-11-13 |
2011-07-14 |
Hanmi Science Co., Ltd. |
Protein complex using immunoglobulin fragment andmethod for the preparation thereof
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
JP2007511604A
(en)
|
2003-11-18 |
2007-05-10 |
アイコニック セラピューティクス インコーポレイティッド |
Homogeneous preparation of chimeric protein
|
EP3378470A1
(en)
|
2003-12-19 |
2018-09-26 |
Novo Nordisk Health Care AG |
Stabilised compositions of factor vii polypeptides
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
US20080089892A1
(en)
|
2004-01-12 |
2008-04-17 |
Eli Lilly And Co. |
Fc Region Variants
|
BRPI0509117A
(en)
|
2004-03-04 |
2007-08-28 |
Wyeth Corp |
lyophilization method to improve crystallization of excipients
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
SI2471813T1
(en)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimized Fc variants
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
PL1824988T3
(en)
|
2004-11-12 |
2018-01-31 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
AU2005307789A1
(en)
|
2004-11-16 |
2006-05-26 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
PL1827483T3
(en)
|
2004-12-15 |
2014-12-31 |
Swedish Orphan Biovitrum Ab Publ |
Therapeutic formulations of keratinocyte growth factor
|
US20060162552A1
(en)
|
2005-01-26 |
2006-07-27 |
Mohawk Valley Energy Solutions, Inc. |
Systems and methods for controlling room air quality
|
KR100754667B1
(en)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
|
US7956160B2
(en)
|
2005-07-22 |
2011-06-07 |
Amgen Inc. |
Concentrated protein lyophilates, methods, and uses
|
MX2008001865A
(en)
|
2005-08-12 |
2008-04-15 |
Human Genome Sciences Inc |
Albumin fusion proteins.
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US7666622B2
(en)
|
2005-10-19 |
2010-02-23 |
Regeneron Pharmaceuticals, Inc. |
Monomeric self-associating fusion polypeptides and therapeutic uses thereof
|
PL1942868T5
(en)
|
2005-11-01 |
2023-12-27 |
Wyeth Llc |
Sodium chloride solution for drug reconstitution or dilution
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
EP1820508A1
(en)
|
2006-02-21 |
2007-08-22 |
CSL Behring GmbH |
Coagulation factor X polypeptides with modified activation properties
|
AU2007223888A1
(en)
|
2006-03-06 |
2007-09-13 |
Amunix, Inc. |
Genetic packages and uses thereof
|
JP5374359B2
(en)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Stabilized polypeptide compounds
|
DK2004683T3
(en)
|
2006-03-24 |
2016-08-22 |
Biogen Hemophilia Inc |
PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
|
PL2631242T3
(en)
|
2006-04-04 |
2023-03-20 |
Takeda Pharmaceutical Company Limited |
A process for concentration of a polypeptide
|
KR101492422B1
(en)
|
2006-04-11 |
2015-02-12 |
체에스엘 베링 게엠베하 |
Method of increasing the in vivo recovery of therapeutic polypeptides
|
KR20090013816A
(en)
|
2006-05-24 |
2009-02-05 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Factor ix analogues having prolonged in vivo half life
|
WO2007144173A1
(en)
|
2006-06-14 |
2007-12-21 |
Csl Behring Gmbh |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
EP2423305A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
WO2008022151A1
(en)
|
2006-08-15 |
2008-02-21 |
Inspiration Biopharmaceuticals, Inc. |
Prophylactic treatment of hemophilia
|
US8015841B2
(en)
|
2006-09-08 |
2011-09-13 |
Praxair Technology, Inc. |
Cryogenic refrigeration system for lyophilization
|
US20100254944A1
(en)
|
2006-09-14 |
2010-10-07 |
Mani Subramanian |
Albumin Fusion Proteins
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
EP2369005B1
(en)
|
2007-06-21 |
2013-04-03 |
Technische Universität München |
Biological active proteins having increased in vivo and/or in vitro stability
|
KR20100058541A
(en)
|
2007-08-15 |
2010-06-03 |
아뮤닉스 인코포레이티드 |
Compositions and methods for modifying properties of biologically active polypeptides
|
US20110154516A1
(en)
|
2007-10-15 |
2011-06-23 |
Stafford Darrel W |
Human factor ix variants with an extended half life
|
WO2009082648A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Inspiration Biopharmaceuticals, Inc. |
Stabilized factor ix formulations containing trehalose
|
NZ598193A
(en)
|
2007-12-27 |
2012-12-21 |
Baxter Int |
Chemically Modified Factor IX
|
TWI538916B
(en)
|
2008-04-11 |
2016-06-21 |
介控生化科技公司 |
Factor vii polypeptides that are modified and uses thereof
|
CA2721362A1
(en)
|
2008-04-16 |
2009-11-19 |
Bayer Healthcare Llc |
Site-directed modification of factor ix
|
CA2721683A1
(en)
|
2008-04-16 |
2009-11-12 |
Bayer Healthcare Llc |
Modified factor ix polypeptides and uses thereof
|
EP2444491B1
(en)
|
2008-04-21 |
2016-11-16 |
Novo Nordisk Healthcare Ag |
Hyperglycosylated human coagulation factor IX
|
MY158228A
(en)
|
2008-04-24 |
2016-09-15 |
Cantab Biopharmaceuticals Patents Ltd |
Factor ix conjugates with extended half-lives
|
CA2729972C
(en)
|
2008-08-05 |
2018-11-20 |
Wyeth Llc |
Lyophilization above collapse
|
JP2012500250A
(en)
|
2008-08-21 |
2012-01-05 |
オクタファルマ アクチェン ゲゼルシャフト |
Recombinantly produced human factor VIII and factor IX
|
CA2737407A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Stabilitech Ltd. |
Method for preserving polypeptides using a sugar and polyethyleneimine
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
ES2730800T3
(en)
|
2009-02-03 |
2019-11-12 |
Amunix Pharmaceuticals Inc |
Extended recombinant polypeptides and compositions comprising the same
|
EP3243835B1
(en)
|
2009-02-11 |
2024-04-10 |
Albumedix Ltd |
Albumin variants and conjugates
|
CN102482340B
(en)
|
2009-04-06 |
2015-05-13 |
诺沃—诺迪斯克有限公司 |
Targeted delivery of factor viii proteins to platelets
|
DK2440228T3
(en)
|
2009-06-08 |
2018-12-17 |
Amunix Operating Inc |
Glucose regulating polypeptides and methods for their preparation and use
|
CN106916229A
(en)
|
2009-06-08 |
2017-07-04 |
阿穆尼克斯运营公司 |
Growth hormone polypeptides and its preparation and application
|
AU2010263058A1
(en)
|
2009-06-18 |
2012-01-12 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
RU2563231C2
(en)
|
2009-06-25 |
2015-09-20 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Factor vii chimeric molecules
|
WO2011017070A1
(en)
|
2009-07-28 |
2011-02-10 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
ES2898683T3
(en)
|
2009-08-27 |
2022-03-08 |
Novo Nordisk As |
Targeting of tissue factor to activated platelets
|
GB2488077A
(en)
|
2009-10-30 |
2012-08-15 |
Novozymes Biopharma Dk As |
Albumin variants
|
EP2353588B1
(en)
|
2010-01-21 |
2015-04-15 |
Agricultural Technology Research Institute |
A sustained release preparation of factor IX
|
AU2011219612A1
(en)
*
|
2010-02-24 |
2012-09-06 |
Arecor Limited |
Stable compositions of Factor IX
|
AR081066A1
(en)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
EA201291482A1
(en)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
CHEMERIC COAGULATION FACTORS
|
CN103140237A
(en)
|
2010-07-09 |
2013-06-05 |
比奥根艾迪克依蒙菲利亚公司 |
Factor ix polypeptides and methods of use thereof
|
ES2561878T3
(en)
|
2010-09-30 |
2016-03-01 |
Toyama Chemical Co., Ltd. |
6-Fluoro-3-hydroxy-2-pyrazinecarboxamide meglumine salt
|
CA2830660A1
(en)
|
2011-05-05 |
2012-11-08 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
CA2863328A1
(en)
|
2012-01-12 |
2013-07-18 |
Biogen Idec Ma Inc. |
Chimeric factor viii polypeptides and uses thereof
|
TR201816253T4
(en)
|
2012-01-12 |
2018-11-21 |
Bioverativ Therapeutics Inc |
Methods for reducing immunogenicity against factor VIII in subjects receiving factor VIII therapy.
|
SI3564260T1
(en)
|
2012-02-15 |
2023-02-28 |
Bioverativ Therapeutics Inc. |
Factor viii compositions and methods of making and using same
|
EP3693000B1
(en)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
EA029685B1
(en)
|
2012-07-11 |
2018-04-30 |
Амуникс Оперэйтинг Инк. |
Factor viii complex with xten and von willebrand factor protein, and uses thereof (embodiments)
|
US20150252345A1
(en)
|
2012-09-25 |
2015-09-10 |
Biogen Idec Ma Inc. |
Methods of Using FIX Polypeptides
|
EP3943102A1
(en)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
EP3318124A3
(en)
|
2013-02-16 |
2018-05-30 |
Albumedix A/S |
Pharmacokinetic animal model
|
TWI788044B
(en)
|
2013-03-15 |
2022-12-21 |
美商百歐維拉提夫治療公司 |
Factor ix polypeptide formulations
|
TWI629993B
(en)
|
2013-03-15 |
2018-07-21 |
美商生物化學醫療公司 |
Factor viii polypeptide formulations
|
CN114736305B
(en)
|
2014-01-10 |
2023-05-05 |
比奥贝拉蒂治疗公司 |
Factor VIII chimeric proteins and uses thereof
|
AU2015236340B2
(en)
*
|
2014-03-24 |
2020-02-06 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
KR20190091292A
(en)
|
2016-12-02 |
2019-08-05 |
바이오버라티브 테라퓨틱스 인크. |
How to Induce Immune Resistance to Coagulation Factors
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|